Randomized FARVATER study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia

Kardiologiya

Volumn 46, Issue 9, 2006, Pages 4-10

  Susekov, A V ^a   Zubareva, M Yu ^a   Tripoten, M I ^a   Rozhkova, T A ^a   Pogorelova, O A ^a   Balakhonova, T V ^a   Masenko, V P ^a   Kukharchuk, V V ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Atherosclerosis; Atorvastatin; C reactive protein; Dyslipidemia; Ischemic heart disease; Low density lipoprotein cholesterol

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FIBRINOGEN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; MASS SCREENING; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOGEN; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; MASS SCREENING; MIDDLE AGED; PYRROLES;

EID: 33750282103     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Schwartz G.G., Ollson A.G., Ezekowitz M.D. et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering. (MIRACLE) study Investigators. Effects of Atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACLE study: a randomized controlled trial. JAMA 2001;285:13:1711-1718.
2. Cannon C.P., Braunwald E., McCabe C.H. et al. Pravastatin or Atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
3. Collhoun H.M., Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:9435:685-696.
4. Sever P.S., Dahlof B., Poulter N.R. et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm. (ASCOT -LLA): a Multicentre controlled lipid-lowering trial. Lancet 2003;361:1149-1158.
5. LaRosa J.C., Grundy S.M., Waters D.D. et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:14:1425-1435.
6. Pedersen T.R., Faergeman O., Kastelein J.J.P. et al. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005;294:19:2437-2445.
7. Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;3:291:1071-1080.
8. Pearson T.A. et al. The Lipid Treatment Assessment Project (LTAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achiving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programm. Eur Heart J 2001;22:554-572.
10. Ganse E. V., Laforest L., Alemao E. et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe:the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:9:1389-1399.
11. Roberts W.L., Multon L., Law T.C. et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implication for clinical and epidemiological applications. Part II. Clin Chem 2001;3:47:418-425.
12. Jones P., Kafonek S., Laurora I., Hunnghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:5:582-587.
13. Andrews T.C., Ballantyne C.V., Hsia J.A. et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2000;111:3:185-191.
14. Karalis D.G., Ross A.M., Vacari R.M. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol 2002;89:6:667-671.
15. Jones P.H., McKenney J.M., Karalis D.G. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evide. Based Cardiovasc Med 2005;9:2:98-101.
16. Schrott H., Fereshetian A.G., Knopp R.H. et al. A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin. J Cardiovasc Pharmacol Ther 1998;3:2:119-124.
17. Assmann G., Cullen P., Heinrich J., Schulte H. Hemostatic variables in the prediction of coronary risk: results of the 8 year follow-up of healthy men in the Munster Heart Study (PROCAM). Prospective Cardiovascular Munster Study. Isr J Med Sci 1996;32:6:364-425.
18. Wierzbicki A.S., Lumb P.J., Chick G., Crook M.A. Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999;53:8:609-611.
19. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
20. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
21. Newman C., Tsai J., Szarek M. et al. Comparative safety of atorvastatin 80 mg vs 10 mg derived from analysis of 49 completed trials in 14236 patients. Am J Cardiol 2006;97:1.